Search

Company Background

Corporate History

Winning the MFIA 2008

Horizon was founded by Dr Chris Torrance and Professor Alberto Bardelli and builds upon a 20 year heritage in oncology research, translational medicine and genome-editing. 

The company is a trusted supplier of genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to almost 800 organizations engaged in bio-pharmaceutical process optimization; drug discovery & development and clinical diagnostic development.   

Under the guidance of Chief Executive Officer, Dr Darrin M Disley since September 2007, the company has made strong commercial progress to become one of the UK’s fastest growing biotechnology companies.1

The Company has attracted a high-quality investor base including DFJ Esprit LLP, Genentech Incorporated, Roche Venture Fund AG, Hargreave Hale, Henderson Global Investors, Henderson Volantis, Invesco Asset Management Ltd, Legal & General Investment Management Ltd, Odey Asset Management LLP, and Dr Jonathan Milner.

 

Scientific Pedigree

Over 300 publications relating to the use of rAAV, GENESIS™, X-MAN™ cell lines and applications thereof have been published in peer-reviewed journals such as Science, Nature, Nature Biotechnology, PNAS, Cancer Cell, Cancer Research, The Journal of American Medical Association and The Journal of Clinical Oncology by Horizon founders, scientific advisers, Center of Excellence sites and research collaborators. The abstracts for these publications can be found in the reference library section of this website.

The company is part of five multi-national grant-funded translational research consortia, is a partner in over 100 academic research collaborations and has established over 30 human gene-editing Centers of Excellence including the US National Institutes of Health (NCI & NHGRI).

 

Intellectual Property

Horizon holds a secure intellectual property position in virally-mediated gene-editing with a patent estate comprising 16 granted patents underpinning the GENESIS™ platform itself. In addition, there are 26 pending patent applications claiming improvements to the platform that reflect the ten-fold improvement in gene targeting efficiency developed by Horizon in the course of industrialization of the platform in 2011-12.

Through the Centers of Excellence program, Horizon allows academic researchers to access our secure IP position in rAAV gene-editing, our nuclease technologies, and our human isogenic disease models for the development of novel cell lines. This open innovation approach has already allowed the creation of additional intellectual property and product pipelines.

1 Deloitte Fast 50 2013, Horizon ranked 1st in the Biotechnology category

Paragraph explaining benefits of Biocair

×

Login Error


There was an error with your login - please try again.

Forgotten your password? Click here

OK ×

Recover your password

Please enter your email address and we'll send you a reset link

×

Thank you.


We've sent you an email to reset your password.

OK ×

Add Voucher


Sorry, Unable to add voucher

OK ×

Account Error


There was an error updating your details.

OK ×

Thank you.


Your changes have been saved.

OK ×

Thank you


Thank you for registering to the Horizon Discovery website. We hope you enjoy and benefit from our online resources, and please feel free to contact us if you have any queries or feedback through the website itself or at info@horizondiscovery.com.


Got a few seconds to tell us what you're interested in?



Tick all that apply:

Horizon’s Offerings

Application Area

Disease Area

 

Other Disease Area (Please specify)


OK
×

Thank you.


Items have been saved to your basket.

OK ×